Xenon to Report Q2 2025 Financial Results on August 11, 2025
VANCOUVER, British Columbia and BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company...
Neuroscience
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery...
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery...
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped...
NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world’s largest TMS outcomes datasetMALVERN,...
BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025
BURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
• Allen Institute to employ Iterative Mapping, Nautilus’ single-molecule proteomics method, to investigate connection between tau protein and Alzheimer’s disease...
AI in Telehealth & Telemedicine Market worth $27.14 Billion by 2030 with 36.4% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., July 29, 2025 /PRNewswire/ -- The global AI in Telehealth & Telemedicine Market, valued at US$2.85 billion...
Creyos Featured in Alzheimer’s Research at AAIC 2025
Findings from Western University, QIMR Berghofer, and Rotman Research Institute underscore the power of Creyos in detecting early risk, validating digital...
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease
- Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration- Trial to assess safety, PK and detect early signs...
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company’s Phase 1b...
Pharmazz Inc. Announces Enrollment of First Patient in Phase 3 Clinical Trial of Sovateltide for Treating Patients with Cerebral Ischemic Stroke
The Phase 3 clinical trial of sovateltide, RESPECT-ETB, is expected to enroll over 500 patients with a primary endpoint of...
Red Light Holland Reports 2025 Audited Year-End Results – Demonstrates Continued Fiscal Discipline, Strategic Growth, and Psilocybin R&D Expansion
Toronto, Ontario--(Newsfile Corp. - July 29, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light...
$10 Million Philanthropic Donation Launches Research Effort into Root Causes of Stuttering
COSTA MESA, Calif., July 28, 2025 /PRNewswire/ -- The newly founded Stuttering Treatment and Research Society (STARS) announced it is the...
Anywhere powered by Linus Health™ Expands Equitable Access to Early Detection of Cognitive Impairment
Fueled by successful community and clinical screenings, Linus Health brings its AI-powered remote cognitive assessment platform to payers, pharma, wellness...
AI Meets Brain Health: League and Linus Health Collaborate to Expand Health Plan Platforms
Bringing early detection of cognitive impairment to the forefront of health plan CX — empowering personalized, proactive brain health BOSTON...
Cumulus Neuroscience Presents Data at AAIC 2025 Annual Meeting and Technology and Dementia Preconference
Analysis of first-in-class CNS-101 study validates that at-home endpoints showed greater separation with Alzheimer's pathology (pTau217) than the benchmark endpoint...
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"),...
TEN RESEARCHERS HONORED AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE
TORONTO, July 27, 2025 /PRNewswire/ -- The Alzheimer's Association® will present 10 scientific awards at the Alzheimer's Association International Conference® 2025...
Weekly Recap: 12 Health Press Releases You Need to See
A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Sanofi's $1.6B acquisition and a groundbreaking...